Bayer (DE000BAY0017) stock is trading in the upper EUR 40s in late August 2026 as investors balance steady Q2 2026 earnings progress with ongoing glyphosate litigation risk highlighted by a court date on September 14, 2026. Per a recent earnings overview as of August 25, 2026, Bayer shares changed hands at EUR 48.71 on Xetra, up 0.47 percent on the day, while the stock has delivered a year-to-date return of 31.99 percent against 7.22 percent for its domestic benchmark index.

Q2 2026 results show modest growth

According to a detailed Q2 2026 breakdown published on August 24, 2026, Bayer generated revenue of EUR 10.872 billion in the second quarter of 2026, an increase of 2.2 percent compared with the prior-year period. In the same quarter, adjusted EBITDA reached EUR 2.144 billion, up 1.9 percent year over year, underscoring that the company is stabilizing its earnings base even as legal issues continue to attract attention. Core earnings per share in Q2 2026 came in at EUR 0.95, which marked a decline of 16.7 percent versus the prior year, while net income improved to EUR 219 million from a net loss of EUR 199 million in the second quarter of 2025, indicating a notable swing back into profitability despite the EPS pressure.

For the first half of 2026, the same report shows that Bayer delivered revenue of EUR 24.277 billion, representing growth of 3.3 percent compared with the first half of 2025. Over the same six-month period, core EPS reached EUR 3.66, up 3.4 percent year over year, suggesting that the EPS drop in the second quarter alone was partly offset by a stronger start to the year.

Guidance and balance sheet targets underpin the outlook

Management kept its full-year 2026 guidance intact, projecting revenue in a range of EUR 44.7 billion to EUR 46.7 billion and core EPS between EUR 4.20 and EUR 4.70. The same guidance framework implies that the company expects the second half of 2026 to contribute between roughly EUR 20.4 billion and EUR 22.4 billion in revenue if the ranges are achieved, compared with the EUR 24.277 billion already booked in the first half.

The earnings update also highlighted progress on deleveraging. Bayer now expects net financial debt at year-end 2026 to fall into a corridor of EUR 29 billion to EUR 30 billion, compared with an earlier target range of EUR 32 billion to EUR 33 billion, representing a tightening of EUR 3 billion at the midpoint. For investors, the combination of maintained earnings guidance and a lower debt target suggests that cash generation and portfolio measures are tracking ahead of earlier expectations.

Segment figures illustrate where that cash generation is coming from. In Q2 2026, the Crop Science division posted revenue of EUR 4.910 billion, increasing 3.5 percent year over year, while adjusted EBITDA for the segment rose to EUR 902 million, a jump of 30.2 percent. The pharmaceutical business contributed revenue of EUR 4.458 billion in the quarter, up 0.8 percent compared with the prior year, and delivered adjusted EBITDA of EUR 1.055 billion, underlining a more measured but still positive earnings profile. These numbers indicate that Crop Science is currently the key earnings growth driver, while Pharma provides a large, relatively stable profit pool.

Litigation calendar and valuation context

Beyond the operating trends, the litigation calendar remains an important driver for Bayer stock. A glyphosate-related hearing scheduled for September 14, 2026 keeps legal risk firmly on the agenda, even as the company continues to emphasize operational improvement and debt reduction. The market has had several weeks to digest the timing of this court date, and recent trading suggests that investors are weighing the potential outcomes against the progress in the core businesses.

On August 24, 2026, Bayer shares were quoted at EUR 47.78 on a major German trading platform, with a last official close of EUR 48.04 and intraday trades between EUR 47.63 and EUR 48.08. On the same date, the stock stood below its 52-week high of EUR 53.92 but well above the 52-week low of EUR 25.78, placing the current level in the upper half of its one-year range. That positioning reflects a significant recovery from last year’s lows while still leaving headroom if the company delivers on its 2026 guidance and litigation developments unfold without major negative surprises.

Additional market data show that on August 25, 2026 the share price closed at EUR 49.26 on Xetra, up 1.61 percent on the session with trading volume of 1,665,853 shares. Intraday in that session, another data source reported that the stock traded at EUR 48.81 in the afternoon, up 0.7 percent at 4:28 p.m. local trading time, after opening at EUR 48.60 and reaching an intraday high of EUR 48.92. These readings confirm that the stock has been trading consistently in a band around the high EUR 40s, with moderate daily swings rather than extreme volatility.

A separate market overview as of August 25, 2026 indicates that the consensus one-year price objective for Bayer shares stands at EUR 56.83 compared with a contemporaneous share price of EUR 48.71, implying theoretical upside potential of roughly 16.7 percent if that average target were to be reached. The same overview lists an estimated earnings date in early November 2026, underlining that the next major scheduled milestone for fundamental data will be the Q3 2026 report.

Product focus: Crop protection solutions

Bayer’s Crop Science division, which produced Q2 2026 revenue of EUR 4.910 billion and adjusted EBITDA of EUR 902 million, is anchored by a broad portfolio of crop protection products, seeds and digital agriculture tools. These include herbicides and fungicides used to protect key crops, as well as advanced seed traits designed to improve yield and resilience, and software platforms that help farmers optimize planting, fertilization and harvest timing based on field-level data.

The strong Q2 2026 EBITDA growth of 30.2 percent in Crop Science shows how this product portfolio can expand profitability when pricing, volumes and cost measures align. For long-term shareholders, the division’s ability to grow earnings faster than revenue is a central part of the investment case, because it suggests that innovation and scale benefits can translate directly into improved margins.

Bayer stock price and investor view

As of August 25, 2026, a comprehensive market snapshot shows Bayer stock at EUR 48.71 on the Xetra exchange, up 0.23 points or 0.47 percent on the day, with the company’s year-to-date total return calculated at 31.99 percent against 7.22 percent for its benchmark index. In that same snapshot, the company is shown with Q2 2026 revenue of EUR 10.87 billion and earnings of EUR 219 million, corresponding to a profit margin of 2.01 percent for the quarter. Together with management’s full-year 2026 guidance range and the tightened net debt target of EUR 29 billion to EUR 30 billion, these figures frame how investors are currently assessing Bayer stock: a company in the midst of operational improvement and balance sheet repair, but still trading under the shadow of a critical September 14, 2026 court date.

Fact box

Company: Bayer AG

ISIN: DE000BAY0017

Ticker: BAYN

Exchange: Xetra

Price (as of August 25, 2026, 3:34 p.m. ET): EUR 48.71

Market cap: EUR 46.85 billion (as of August 24, 2026)

Sector / Industry: Pharmaceuticals, crop science and consumer health

Index membership: DAX


Disclaimer…